Scarica l'app Stockscreener
0.2269
2.70%
-0.0063
Dopo l'orario di chiusura:
.22
-0.0069
-3.04%
Precedente Chiudi:
$0.2332
Aprire:
$0.22
Volume 24 ore:
10.33M
Relative Volume:
1.68
Capitalizzazione di mercato:
$8.06M
Reddito:
$94,000
Utile/perdita netta:
$-13.28M
Rapporto P/E:
-0.0311
EPS:
-7.2965
Flusso di cassa netto:
$-11.67M
1 W Prestazione:
-2.91%
1M Prestazione:
-13.73%
6M Prestazione:
-67.59%
1 anno Prestazione:
-91.23%
Intervallo 1D:
$0.215
$0.2298
Intervallo di 1 settimana:
$0.215
$0.24
Portata 52W:
$0.1901
$2.977
AIM ImmunoTech Inc Stock (AIM) Company Profile
Nome
AIM ImmunoTech Inc
Settore
Industria
Telefono
352 448 7797
Indirizzo
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.2269 | 8.28M | 94,000 | -13.28M | -11.67M | -7.2965 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
AIM ImmunoTech Inc Borsa (AIM) Ultime notizie
AIM ImmunoTech Converts ~$450,000 of Note Into 1.92M Shares in Exchanges With Streeterville - TradingView
AIM ImmunoTech Highlights Scientific Rationale, Supportive - GlobeNewswire
AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead - Stocktwits
Why Did AIM Stock Plummet 35% Today? - Stocktwits
AIM ImmunoTech Eliminates $1.22 Million Debt via Stock Exchange - Minichart
Aim Immunotech Stock Price Forecast. Should You Buy AIM? - StockInvest.us
AIM ImmunoTech Extinguishes Debt Through Equity Exchanges - TipRanks
AIM ImmunoTech Secures Ampligen Patent Protection in Europe - Intellectia AI
AIM ImmunoTech Significantly Expands Ampligen® Global - GlobeNewswire
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - The Manila Times
AIM ImmunoTech Secures European and U.K. Patent Protection for Ampligen in Long COVID Through 2041 - quiverquant.com
AIM ImmunoTech Extends IP Protection for Ampligen Through 2039 with Broad US Patent - Contract Pharma
AIM Looks 69.6% Undervalued on GF Value™ Despite Financial Distr - GuruFocus
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 - The Manila Times
AIM ImmunoTech Secures U.S. Patent for Ampligen Combination with Pembrolizumab in Cancer Treatment - Quiver Quantitative
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod - GlobeNewswire
AIM Q2 2026 Earnings: Wider Than-Expected Loss as Clinical-Stage Costs PersistProfit Inflection Point - vinanet.vn
AIM ImmunoTech Inc. (AIM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
AIM ImmunoTech Inc. (AIM) Key Financial Ratios – Valuation, Profitability & More - Value Research
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - The Manila Times
AIM ImmunoTech doses final patient in pancreatic cancer trial - stocktitan.net
AIM ImmunoTech Participates in the Virtual Investor 'Why Now' On-Demand Conference - Moomoo
AIM | AIM ImmunoTech Inc. FinancialsRevenue Breakdown - quiverquant.com
AIM ImmunoTech highlights pancreatic cancer program momentum - scanx.trade
AIM ImmunoTech (AIM) Stock Forecast & Analyst Ratings - Moomoo
AIM Maintained by Ascendiant Capital -- Price Target Lowered to $7.00 - GuruFocus
AIM (AIM) Earnings Snapshot: EPS Does Not Reach the Reported Estimate in the Latest Reading; After Earnings: The Share Price Adds 1.84% in the Latest SessionHigh Estimate Range - vinanet.vn
AIM ImmunoTech Q2 2026 Earnings: EPS Misses by Wide Margin as Shares Drop SharplyRevenue Guidance Range - dars.gov.et
AIM Q2 2026 Earnings: Wider-than-Expected Loss Prompts Investor CautionFinal Results - vinanet.vn
AIM ImmunoTech Inc (AIM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
$AIM ImmunoTech (AIM.US)$ - Moomoo
Analysts’ Opinions Are Mixed on These Healthcare Stocks: AIM ImmunoTech (AIM) and Schrodinger (SDGR) - The Globe and Mail
Maxim Group Maintains AIM ImmunoTech(AIM.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article - The Manila Times
AIM's Ampligen-Treated Mouse Group Had 100% Ebola Survival - Stock Titan
AIM ImmunoTech CEO Urges Biodefense Military Integration - The Globe and Mail
Form 8K AIM ImmunoTech Inc For: 11 August By Investing.com - Investing.com Nigeria
Biodefense is force protection: Ready today, prepared for tomorrow - Breaking Defense
AIM ImmunoTech Releases Q2 2026 Financial Results - AlphaStreet
Form 8K AIM ImmunoTech Inc For: 10 August By Investing.com - Investing.com Australia
AIM ImmunoTech Q2 loss widens to $3.8M, EPS misses estimates - scanx.trade
AIM ImmunoTech Reports Completion of Phase 2 Ampligen Dosing in Metastatic Pancreatic Cancer Trial, Advances Phase 3 Planning - Quiver Quantitative
AIM ImmunoTech Reports Q2 2026: $9.9M Cash, $3.8M Net Loss - TradingView
AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer - The Manila Times
AIM Completes Pancreatic Cancer Study Dosing; Phase 3 Planned - Stock Titan
AIM ImmunoTech (NYSE: AIM) returns to positive equity after new financings - Stock Titan
AIM ImmunoTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
AIM ImmunoTech Inc (AIM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 8K AIM ImmunoTech Inc For: 6 August By Investing.com - Investing.com Nigeria
AIM ImmunoTech signs $1.5 million manufacturing agreement with Sterling Pharma - Investing.com
AIM ImmunoTech (AIM) inks $1.5M manufacturing pact for Ampligen - Stock Titan
AIM ImmunoTech Inc Azioni (AIM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):